Background/Objectives: Few studies have shown that supplementation with micronutrients (MNs) or n-3 fatty acids may have health benefits such as reduced morbidity in schoolchildren. The effect of a combination of these nutrients has never been investigated. This study aimed to determine the effect of a combination of two different doses of MN and n-3 fatty acids on morbidity in schoolchildren in Bangalore, India. Subjects/Methods: In all 598 children (6-10 years) received foods fortified with either high (100% recommended dietary allowance) or low (15% recommended dietary allowance) MN, combined with either high (900 mg a-linolenic acid (ALA) plus 100 mg docosahexaenoic acid) or low (140 mg ALA) n-3 fatty acids for 1 year. Morbidity was measured by weekly self-reports using a structured questionnaire. Poisson regression analyses of episodes/child/year and duration/episode adjusted for age and sex were performed on clusters of symptoms, including upper and lower respiratory tract infections (URTI and LRTI), gastrointestinal complaints (GI) and general symptoms of illness to observe MN and n-3 fatty acid treatment effects. Conclusion: Although n-3 fatty acids may be beneficial for reducing illness in Indian schoolchildren, more research is needed to confirm presence of combined effect with MN.
Introduction
Micronutrient (MN) deficiencies have been shown to be prevalent in children in developing countries, even within urban middle class populations (Diaz et al., 2003; Srihari et al., 2007) . Although a great deal of attention has focused on the high prevalence of iron deficiency anemia in India , in most circumstances, iron deficiency is just one of many MN deficiencies resulting from poor quality diets (Ramakrishnan, 2002) . For example, the prevalence of various MN deficiencies among school going children reported by different studies are 40% for iron deficiency anemia (Allen et al., 2006) , 80% for riboflavin deficiency, 30% for vitamin B 12 deficiency (Vaz et al., in press) , 23% for vitamin A deficiency (Singh and West, 2004) and high levels of zinc deficiency (Brown et al., 2004; Muthayya et al., 2009b) . Some MN have general antioxidant properties, whereas others, such as zinc and vitamin A, are directly related to child morbidity and mortality (Sazawal et al., 1998; Black 2003; Imdad et al., 2010) . However, rather than single MN effects, it is important to look at multiple MN supplementation, as many MN deficiencies occur at the same time. Multiple MN supplements may have a small effect on infectious morbidity (Allen et al., 2009) , although the effects of different intervention trials have not been consistent. For example, in pre-school children, multiple MN supplements have been shown to be associated with lower respiratory or GI morbidity (Sharieff et al., 2006; Sazawal et al., 2007; Manger et al., 2008) , but other studies have shown no effects (Smuts et al., 2005) .
The intake of long chain n-3 poly unsaturated fatty acids (n-3 LCPUFA) is low in India (Muthayya et al., 2009a, b) , owing to the lack of marine foods. These fatty acids have been shown to be important in early development and cognition (Martinez, 1992; McCann and Ames, 2005; Eilander et al., 2007) . Although we previously did not observe a significant effect of n-3 fatty acid supplements on cognition in schoolchildren (Muthayya et al., 2009b) , they have been implicated in the modulation of inflammatory processes and immune function (Galli and Calder, 2009; Ratnayake and Galli, 2009 ). Most research efforts have focused on investigating the effect of n-3 fatty acids in relation to chronic diseases (Uauy and Castillo, 2003; Kris-Etherton et al., 2007) . The effect of an n-3 PUFA supplement on acute infectious morbidity in children over a long intervention period has not been studied extensively.
The present study was designed to investigate the effect of a high or low dose of multiple MN in combination with a high or low dose of an n-3 fatty acid given in fortified food products, on infectious disease morbidity and immune function in Indian school children over the period of 1 year.
Methods
The present study was part of a larger intervention trial carried out to assess the effect of a multiple MN and/or n-3 fatty acids on growth and cognition in Indian school children aged 6-10 years. The main study method has been reported elsewhere (Muthayya et al., 2009b) . This study, called the CHAMPION (Children's Health And Mental Performance Influenced by Optimal Nutrition) study, was conducted between November 2005 and March 2007 among marginally nourished children attending two primary schools in Bangalore, India, which serve communities from a poor socio economic background in the vicinity. Informed, written consent from the parents and verbal assent from their children was obtained in 645 parent-child pairs. The protocol of the study was approved by the ethical committees at St John's National Academy of Health Sciences, Bangalore, India and Wageningen University, The Netherlands.
Of 645 children who were initially selected because they fulfilled inclusion criteria, 598 were randomly assigned to the study intervention groups. The study used a randomized, double-blind, controlled, 2 Â 2 factorial design, with four parallel treatment groups providing 100% recommended dietary allowance (high) or 15% recommended dietary allowance (low) concentrations of MN (including iodine, iron, vitamin B 2 , vitamin B 6 , vitamin B 12 , folate, zinc, calcium, vitamin A and vitamin C) and/or high (900 mg a-linolenic acid (ALA) plus 100 mg docosahexaenoic acid (DHA)) or low (140 mg ALA) concentrations of n-3 fatty acids as follows: (1) High MN and high n-3 fatty acid treatment, (2) low MN and high n-3 fatty acid treatment, (3) high MN and low n-3 fatty acid treatment and (4) low MN and low n-3 fatty acid treatment. The low MN treatment delivered micronutrients per kcal proportional to that consumed by the children in their habitual diet. The high n-3 fatty acid treatment contained 50% of the recommended intake of ALA for children aged 2-12 years (Kris-Etherton et al., 2007) and 100 mg DHA, which corresponds with B50% of the advisable daily fish intake for children (Kris-Etherton et al., 2007) . The low n-3 treatment provided 15% of the amount provided by the high n-3 fatty acid treatment, and no DHA. All treatment groups consumed two fortified products daily: a fruit flavored wheat biscuit with a creamy filling inside and a flavored milk powder drink providing 420 kcal and 13.5 g protein per day. All children received the intervention in a randomized manner for a period of 12 months. Detailed descriptions of the intervention products have been published elsewhere (Muthayya et al., 2009b) .
The morbidity of the children was assessed by the daily recording of information on morbidity by the study monitors and medical study staff. On Mondays and after holidays, the children were asked about illness on the preceding Sunday and the preceding holiday. When a child had been ill, details about the illness were collected by means of a standardized morbidity questionnaire, administered to the parents/caregivers of sick children during home visits by medical study staff. Information about occurrence and duration of common symptoms of infectious illnesses (such as diarrhea, respiratory infections including colds, cough, difficult breathing, diagnosed pneumonia and fever) during the period of illness was obtained. In addition, the parents/ caregivers of the child were asked about any possible hospital, clinic or doctor visit. For statistical analyses, the illnesses based on symptoms were grouped into four clusters, including (1) upper respiratory tract infection ((URTI): ear pain, running nose, sore throat), (2) lower respiratory tract infection ((LRTI): breathing difficulty, wheezing, cough and sputum), (3) gastrointestinal (GI) related clusters of symptoms: blood in stool, poor appetite, diarrhea and abdominal pain and (4) general symptoms of illness: tiredness and fever. An episode was considered new if there was at least one illness free day preceding it. For each of the four clusters of illness and for total illness days, the number of episodes per child per year (incidence) and mean duration of episode per illness group per child were calculated.
Immune response was determined by comparing changes in antibody titres following vaccination against hepatitis B (ENGERIX-B, GlaxoSmithKline Biologicals, Rixensart, Belgium). A specific immune response to the hepatitis B n-3 fatty acids, micronutrients and morbidity T Thomas et al vaccine would result in increased levels of antibodies against the HBsAg (anti-HBsAg). Plasma HBsAg titres were measured after 12 months of intervention, which was 1 month after the first dose of vaccination. To test the hypothesis that the intervention would improve the immune response we chose to measure the early response, before antibody levels reached plateau. The vaccine was administered intramuscularly to children in the 11th month of the study in a dose of 10 mg in 0.5 ml. In order to complete the vaccination course, the remaining two doses were given after completion of the intervention study; the second dose was given directly after the final blood collection in the 12th month of the study and the third vaccination was given 6 months later. Children with HBsAg 4 10IE/L were considered as responders to the vaccine and the others as non-responders. Plasma HBsAg and HBcAg titres were assessed by means of electrochemiluminescence (Roche Elecsys, 2010, Roche Diagnostics, Mannheim, Germany).
Person days of surveillance was considered to account for the longitudinal study design and the reporting of multiple incidents of a disease episode by a single subject and drop out. This accounts for disproportional missing data in the groups. Baseline data comparisons for various parameters were performed using analysis of variance and w 2 -test. The incidence and duration of the episodes of illness clusters and total illness were transformed using a Poisson distribution. Regression analyses, adjusting for age and sex were performed on incidence and duration of the episodes of illness clusters to examine the effect of the high versus low MN treatments and that of high versus low n-3 fatty acid treatments. Relative risk (95% confidence interval (CI)) of occurrence of illness in high treatment arm as compared with low treatment for both MN and n-3 fatty acid are reported. Plots of the cumulative weekly median duration of illness were also made to visually assess if and when the groups of children diverged in illness behavior. For secondary analyses, Spearman's Rank Correlations were calculated between the change in weight and height over the 12 months intervention period with episode/child/year and duration/episode. An alpha level of less than 0.05 was considered significant. All analyses were performed using SPSS version 13.0 (SPSS Inc., Chicago, IL, USA) and SAS version 9.1 statistical software package (SAS Institute Inc., Cary, NC, USA).
Results
Of the 598 children included in the study, 550 completed the intervention. Data of all 598 children included in the study were used for morbidity analysis and data of 546 children were available for analysis of immune function. There were no significant differences between the four intervention groups with regard to baseline characteristics (Table 1) . After 12 months of intervention, the effect of the high MN treatment compared with the low MN treatment was clearly reflected in the biochemical measurements of MN status, and the membrane erythrocyte status of ALA, eicosapentaenoic acid and DHA was significantly increased following the high n-3 fatty acid treatment (Muthayya et al., 2009b) .
Children consuming high n-3 fatty acids had a significantly reduced risk for episodes of URTI compared with children in the low n-3 fatty acid groups (relative risk (RR) ¼ 0.88; 95% CI: 0.79, 0.97, P ¼ 0.014) ( Table 2 ). There were B5% fewer events/child/year in the high n-3 fatty acids group. Similarly significant positive effects on duration/ event were found for URTI (RR ¼ 0. There was a synergistic interaction effect of the MN intervention on the high n-3 fatty acid intervention for duration of GI complaints (RR ¼ 0.79; 95% CI: 0.71, 0.87, Po0.001); and an antagonistic interaction effect of the MN on high n-3 fatty acid intervention for duration of general symptoms of illness (RR ¼ 1.06; 95% CI: 1.02, 1.11, P ¼ 0.007) and URTI episodes (RR ¼ 1.22; 95% CI: 1.14, 1.32, Po0.001). n-3 fatty acids, micronutrients and morbidity T Thomas et al
When the median cumulative duration of illness was plotted across weeks of intervention within the low and high n-3 fatty acid groups (Figure 1) , there was a divergence between the low and high n-3 fatty acid plots from week 22 from which point the high n-3 fatty acid group reported shorter duration of illness in comparison with the low n-3 fatty acid group. No differences were observed in cumulative duration of illness between the low and high MN group.
Of the children whose anti-HBsAg antibody titres were available, 37% responded to the vaccination and this was not significantly different between the high and low MN groups (37% vs 36%, P ¼ 0.696) nor between the high and low n-3 fatty acid groups (37% vs 38%, P ¼ 0.955). Median (25th and 75th percentiles) anti-HBsAG titres were two (2 and 56) for the high MN and high n-3 fatty acid group; two (2 and 36) for the high MN and low n-3 fatty acid group; two (2 and 45) for the low MN and high n-3 fatty acid group and; and two (2 and 62) for the low MN and low n-3 fatty acid group. There were no significant differences between the low and high n-3 fatty acid groups, or the low and high MN groups. As the response can be confounded by prior exposure to hepatitis B, such that a boosting type of antibody response could be observed with the vaccination, antibody titers to the core antigen (HBcAg) were also measured. However, even after removing those children with high HBcAg antibody titers, there were no differences between groups.
Discussion
This study shows that there is a positive effect of the high n-3 fatty acid intervention compared with the low n-3 fatty acid intervention group on the incidence of episodes of URTI and duration/episode of URTI, LRTI, GI complaints and general illness. For the high MN intervention, there was a significant, but smaller positive effect on the duration of episodes of general morbidity symptoms.
This was a rigorously conducted intervention trial in a large group of 598 children where the compliance for ingestion of the intervention product was 75% for the biscuits and 70% for the drink. The measurement of morbidity in the current study was conducted through selfreports by the children. In order to ensure the quality of the data, re-assessments of these self-reports were randomly conducted by senior staff on 5% of the children and compared with those of the study staff. These control checks hardly showed any differences.
The positive findings of the high n-3 fatty acid treatment on morbidity in our study are similar to findings of a study conducted in Thailand, in which n-3 PUFA supplements were given for a period of 6 months to children aged 9-12 years (Thienprasert et al., 2009) . In that study, a much higher dose of n-3 PUFA of 200 mg eicosapentaenoic acid plus 1 g DHA daily supplementation was given for 5 days per week. In the intervention arm, 10% fewer subjects reported illness n-3 fatty acids, micronutrients and morbidity T Thomas et al and the number of episodes of illness per subject were also lower, when compared with the placebo arm. Similarly, a study in the US in 18-36 months old children showed that children consuming 130 mg DHA per day toddler formula for 60 days experienced significantly fewer respiratory illnesses compared with children consuming an unfortified toddler formula (Minns et al., 2010) . Furthermore, two studies in school children found a significant reduction in the number of days absent from school after supplementation with 650 mg DHA and 100 mg eicosapentaenoic acid/day for 3 months (Hamazaki et al., 2008) or a fish-flour enriched spread delivering 892 mg DHA per week for 6 months (Smuts et al., 2005) ; this may indirectly imply that children were ill for fewer days after DHA supplementation versus control children. Compared with these other studies, our study provided a much lower dose of DHA relative to the children's body weight of 100 mg DHA in the high n-3 fatty acid treatment group. It is possible that the high dose of 900 mg ALA provided in the high n-3 fatty acid arm in our study also may have contributed to the effect on morbidity through conversion of ALA into eicosapentaenoic acid and DHA. Parenthetically, in the gastrointestinal symptoms it may be noted that the significant effects observed were more related to mild symptoms such as lack of appetite or abdominal pain rather than for more serious symptoms such as diarrhea. It is reasonable to surmise that this might have been because of the pre existing low incidence (0-1 events per child/year) of more serious symptoms in this group of children. For example, the incidence of diarrhea in the first one month of intervention was only 0.3 per 100 days, which is comparable to incidences reported in other school-aged children (Sarma et al., 2006) but much lower than incidences reported in younger children (4.86 episodes per 100 days) (Penny et al., 2004) .
There was no significant correlation between the duration of morbidity and the weight or height gain over the intervention period after adjusting for age, which indicated that the growth of the child during the intervention period was not associated with observed morbidity. This finding seems to suggest that the association between morbidity and growth, frequently observed in younger children, may be less relevant in school-aged children. The decrease in incidence and duration of illness in children receiving the high n-3 fatty acid intervention might be attributable to an enhanced resistance to infections or an effect on alleviation of symptoms that might be related to allergy as running nose and cough were predominant symptoms related to the respiratory system that were reported in this study (Median:3 events and 2 events/year, respectively). A dietary benefit of n-3 LCPUFA in controlling inflammatory disorders like asthma and irritable bowel syndrome has been suggested in the literature (Galli and Calder 2009) . Increasing the cellular uptake of n-3 fatty acids has been suggested to cause an enhancement in the production of resolvins and protectins, which are thought to dampen and resolve inflammatory responses (Serhan et al., 2002) . Furthermore, it has recently been shown in an in vitro model that dietary n-3 LCPUFA can prevent the migration of neutrophils, which is a key step in inflammation (Tull et al., 2009 ). Another recent report shows that n-3 LCPUFA may exert clinical effects via their capacity to regulate the expression of signal transduction genes and genes for proinflammatory cytokines (Weaver et al., 2009) . As antibody responses to vaccination were not different between the treatment groups we can only hypothesize that the improved resistance to disease observed in this study is caused by modulation of the immune response.
The present study did not show significant differences in incidence and duration of morbidity between the high and low MN groups, except for a shorter duration for the general illness cluster. Our findings are in contrast to findings from three other trials in school children, which all showed benefits of a multiple MN supplementation on morbidity. A study in Thai children of 5-13 years of age, demonstrated a significantly beneficial effect of a MN fortified seasoning powder on the incidence of respiratory-related illness such as cough and runny nose and diarrhea (Manger et al., 2008) . Similarly, in Indian children aged 5-14 years, a multiple MN fortified beverage was effective in reducing the mean duration of illness significantly with 2.4 days compared with an unfortified beverage (Sarma et al., 2006) . Furthermore, South African children aged 6-11 years receiving a fortified biscuit and drink with iron, iodine, vitamin C and b-carotene for 12 months missed significantly fewer school days owing to respiratory-related illness (14 days/100 children) and diarrhea (17 days/100 children) compared with control children (van Stuijvenberg et al., 1999) . n-3 fatty acids, micronutrients and morbidity T Thomas et al
In contrast, and similar to the present study, supplementation with iron and zinc did not result in a reduction of severe diarrhea in Bangladeshi infants (Baqui et al., 2003) or in Peruvian children who received zinc along with vitamins and other minerals (Sarma et al., 2006) . Two other studies in different settings have also shown negligible impact of MN supplementation on morbidity (Lopriore et al., 2004; Kelly et al., 2008) . These findings and our findings may suggest that although the role of zinc in enhancing host resistance to disease is well documented, the same may not be true when zinc is provided together with multiple micronutrients. The dose of zinc used in the high MN group in the present study was similar to that in the other studies (about 10 mg per day). However, the control group in our study received 1.7 mg zinc/day in contrast to most of the other studies, which included a true control group. Therefore, it may be possible that the difference between the high and low dose of zinc in our study may not have been large enough to enable detection of differences in morbidity. In addition, the children in our study may not have been severely zinc depleted at baseline as has been observed from recent unpublished studies on children from similar background. Comparisons between studies are difficult owing to different combinations of micronutrients used, different dosages and carriers, and different characteristics (age, deficiency status and other infectious diseases) of the study population. Therefore, clearly more research is needed to evaluate the impact of multiple micronutrients on morbidity in school-aged children using different combinations and different dosages of multiple micronutrients.
The synergistic interaction effect of high MN treatment and high n-3 fatty acid treatments on duration of gastrointestinal complaints and the antagonistic interaction effect on duration of upper RTI have not been observed elsewhere and cannot be explained, because the high MN treatment did not have an independent effect on these morbidity clusters.
In this study, disease duration and incidence and antibody titer to hepatitis B vaccine were used for analyzing immune function. However, these two methods determine only some aspects of immunity while many remaining aspects, for example, changes happening at molecular level would not be detected.
In conclusion, this study shows that a high dose of n-3 fatty acids, including 900 mg ALA and 100 mg DHA, may reduce the duration of morbidity and the incidence of URTI compared with a low dose of n-3 fatty acids of 140 mg ALA in school children in India. In contrast, no major effects of the high compared with the low MN treatments were found on incidence and duration of morbidity. Future research will be needed to confirm the effects and to establish an optimal dose of n-3 fatty acids for the reduction of illness and to further investigate the potential beneficial role of multiple MN alone or in combination with n-3 fatty acids in children's resistance to disease.
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